Lumos Pharma to Present at APPES 2024

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company specializing in treatments for rare diseases, recently announced that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society (APPES) 2024. This event will take place from October 2-5, 2024, in New Delhi, India. The trial investigates the efficacy of oral LUM-201 in treating Pediatric Growth Hormone Deficiency (PGHD).

Scheduled for October 3rd, the presentation will be delivered by Professor Paul Hofman, MD, from the Liggins Institute at the University of Auckland, New Zealand. The presentation will occur during the Oral Session: Growth & Puberty at 2:30 PM local time. The abstract titled "Growth, IGF-1 and IGFBP-3 Responses to the Oral Growth Hormone (GH) Secretagogue, LUM-201, in Pediatric Growth Hormone Deficiency (PGHD) in the OraGrowtH210 Trial" will delve into the trial's findings.

Lumos Pharma, Inc. focuses on developing and commercializing treatments for rare diseases. The company is led by a team with extensive experience in rare disease drug development. Their leading therapeutic candidate, LUM-201, is an innovative oral growth hormone (GH) secretagogue aimed at changing the approximately $4.7 billion global GH market from injectable to oral therapy. LUM-201 is undergoing multiple Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in the United States and the European Union.